As the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.
Mohit Jain
Advertisement
Articles by Mohit Jain
Advertisement
Latest Updated Articles
505(b)(2): A Pathway to Competitiveness Through Innovation for Specialty and Generic CompaniesPublished: December 4th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
How Will the Inclusion of GLP-1s in Medicaid and Medicare Impact Businesses?
2
How are New FDA Programs Impacting Neuroscience?
3
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
4
Will the Industry Continue to Research Psychedelics?
5
